These findings, along with the clinical success of the BCR signaling inhibitors such as ibrutinib and acalabrutinib (72, 73), highlight the importance of BCR signaling for survival and proliferation of CLL cells. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.